Search Result

Results for "

GTPγS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adenylate Cyclase (2) Arrestin (2) Cannabinoid Receptor (1) CCR (2) GPR109A (1) GPR84 (1) LPL Receptor (1) mGluR (4) Opioid Receptor (3) P2X Receptor (1) P2Y Receptor (3)
By Research Areas:	Cancer (1) Cardiovascular Disease (7) Inflammation/Immunology (6) Neurological Disease (11)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137677B

GTPγS tetralithium	Others	Others
GTPγS (tetralithium) is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS (tetralithium) to couple with G- protein α, to study its effect on kinase activity. GTPγS (tetralithium) acts as a component of lysis buffer .

HY-111454

SR17018

1 Publications Verification

Opioid Receptor Neurological Disease

SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC₅₀ of 97 nM.
HY-115748

Mant-GTPγS

Adenylate Cyclase Cardiovascular Disease

Mant-GTPγS, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS is a potent YdeH inhibitor .

SR17018 1 Publications Verification	Opioid Receptor	Neurological Disease
SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC₅₀ of 97 nM.

Mant-GTPγS	Adenylate Cyclase	Cardiovascular Disease
Mant-GTPγS, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS is a potent YdeH inhibitor .

HY-115748A

*Mant-GTPγS* triammonium**	Adenylate Cyclase	Cardiovascular Disease
Mant-GTPγS triammonium, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS triammonium is a potent YdeH inhibitor .

HY-128128

ASN04421891	Others	Neurological Disease
ASN04421891 is a potent GPR17 receptor modulator, with an EC₅₀ of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research .

HY-10680

MK-6892 4 Publications Verification	GPR109A	Cancer
MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. K_i and GTPγS EC₅₀ of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.

HY-113667

ASN04885796	Others	Cardiovascular Disease Neurological Disease
ASN04885796 (compound IV) is an GPR17 activator with an EC₅₀ of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases .

HY-128111

ASN02563583	Others	Neurological Disease
ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC₅₀ value of 0.64 nM in [₃₅S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases .

HY-15799

AZD1283	P2Y Receptor	Cardiovascular Disease
AZD1283 is a potent P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀ of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .

HY-116088

W123	LPL Receptor	Inflammation/Immunology
W123, a FTY720 analog, is a competitive sphingosine 1-phosphate type 1 (S1P1) receptor antagonist. W123 is measured by GTPγS activation, MAPK recruitment, cell migration, and ligand-induced receptor internalization .

HY-151100

GPR84 antagonist 3	GPR84	Inflammation/Immunology
GPR84 antagonist 3 (compound 42) is a potent GPR84 (G-protein-coupled receptor 84) antagonist. GPR84 antagonist 3 inhibits GTPγS, with a pIC₅₀ of 8.28. GPR84 antagonist 3 has a favorable pharmacokinetic profile suitable .

HY-108656A

MRS2365 trisodium	P2Y Receptor Arrestin	Cardiovascular Disease
MRS2365 trisodium is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM)/*[ ³⁵S]GTPγS* binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity .

HY-151899

A3AR modulator 1	Adenosine Receptor	Inflammation/Immunology
A3AR modulator 1 (MRS8054) is an orally active A3 adenosine receptor (A3AR) (Adenosine Receptor) positive allosteric modulator (PAM). A3AR modulator 1 greatly enhances Cl-IB-MECA-stimulated [ ³⁵S]GTPγS binding E_max .

HY-103364A

C-021 dihydrochloride 1 Publications Verification	CCR	Inflammation/Immunology
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-120645

BMS-986122	Opioid Receptor	Neurological Disease
BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ ³⁵S]GTPγS binding in mouse brain membranes .

HY-103364

C-021 1 Publications Verification	CCR	Inflammation/Immunology
C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-107721

(±)-J-113397	Opioid Receptor	Neurological Disease
(±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a K_i of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC₅₀ value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .

HY-122255

LY487379	mGluR	Neurological Disease
LY487379 is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 can be used for schizophrenia research .

HY-103565

AMN082	mGluR	Neurological Disease
AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-118140

ZCZ011	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .

HY-103552

LY487379 hydrochloride	mGluR	Neurological Disease
LY487379 hydrochloride is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 hydrochloride potentiates glutamate-stimulated [ ³⁵S]GTPγS binding with EC₅₀ values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 hydrochloride promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 hydrochloride can be used for schizophrenia research .

HY-108656

MRS2365	P2Y Receptor Arrestin	Cardiovascular Disease
MRS2365 is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM) /*[ ³⁵S]GTPγS* binding/β-arrestin 2 recruitment agonist with an EC₅₀ of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .

HY-103565A

AMN082 free base	mGluR	Neurological Disease
AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC₅₀ values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .

HY-12927

SX-517
SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca ²⁺ flux (IC₅₀=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC₅₀=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model .

HY-112461A

NF449 octasodium 1 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

GTPγS

Inhibitors & Agonists